Related content

A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

By Cigler T.  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 453-461

Springer Publishing Company

Access to resources Recommend Favorite

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment

By Kvinnsland S.   Anker G.   Dirix L.-Y.   Bonneterre J.   Prove A.-M.   Wilking N.   Lobelle J.-P.   Mariani O.   di Salle E.   Polli A.   Massimini G.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 976-982

Elsevier

Access to resources Recommend Favorite

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

By Skedgel C.   Rayson D.   Dewar R.   Younis T.  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 325-333

Springer Publishing Company

Access to resources Recommend Favorite

Exemestane: A Review of its Use as Adjuvant Treatment for Early Breast Cancer in Postmenopausal Women

By Moen Marit D.   Wagstaff Antona J.  

American Journal of Cancer, Vol. 5, Iss. 4, 2006-01 ,pp. : 259-272

Adis International

Access to resources Recommend Favorite